1	Two	_	CD	_	_	4	NMOD	_	_
2	major	_	JJ	_	_	4	NMOD	_	_
3	drug	_	NN	_	_	4	NMOD	_	_
4	companies	_	NNS	_	_	5	SBJ	_	_
5	posted	_	VBD	_	_	0	ROOT	_	_
6	strong	_	JJ	_	_	8	NMOD	_	_
7	third-quarter	_	NN	_	_	8	NMOD	_	_
8	earnings	_	NNS	_	_	5	OBJ	_	_
9	,	_	,	_	_	5	P	_	_
10	in	_	IN	_	_	5	ADV	_	_
11	line	_	NN	_	_	10	PMOD	_	_
12	with	_	IN	_	_	11	NMOD	_	_
13	profits	_	NNS	_	_	12	PMOD	_	_
14	already	_	RB	_	_	15	TMP	_	_
15	reported	_	VBN	_	_	13	APPO	_	_
16	by	_	IN	_	_	15	LGS	_	_
17	industry	_	NN	_	_	18	NMOD	_	_
18	leaders	_	NNS	_	_	16	PMOD	_	_
19	and	_	CC	_	_	13	COORD	_	_
20	analysts	_	NNS	_	_	22	NMOD	_	_
21	'	_	POS	_	_	20	SUFFIX	_	_
22	expectations	_	NNS	_	_	19	CONJ	_	_
23	.	_	.	_	_	5	P	_	_

1	But	_	CC	_	_	10	DEP	_	_
2	Pfizer	_	NNP	_	_	10	SBJ	_	_
3	Inc.	_	NNP	_	_	2	POSTHON	_	_
4	,	_	,	_	_	2	P	_	_
5	based	_	VBN	_	_	2	APPO	_	_
6	in	_	IN	_	_	5	LOC	_	_
7	New	_	NNP	_	_	8	NAME	_	_
8	York	_	NNP	_	_	6	PMOD	_	_
9	,	_	,	_	_	2	P	_	_
10	reported	_	VBD	_	_	0	ROOT	_	_
11	flat	_	JJ	_	_	12	NMOD	_	_
12	earnings	_	NNS	_	_	10	OBJ	_	_
13	.	_	.	_	_	10	P	_	_

1	Schering-Plough	_	NNP	_	_	10	SBJ	_	_
2	Corp.	_	NNP	_	_	1	POSTHON	_	_
3	,	_	,	_	_	1	P	_	_
4	based	_	VBN	_	_	1	APPO	_	_
5	in	_	IN	_	_	4	LOC	_	_
6	Madison	_	NNP	_	_	5	PMOD	_	_
7	,	_	,	_	_	6	P	_	_
8	N.J.	_	NNP	_	_	6	APPO	_	_
9	,	_	,	_	_	6	P	_	_
10	reported	_	VBD	_	_	0	ROOT	_	_
11	a	_	DT	_	_	14	NMOD	_	_
12	21	_	CD	_	_	13	AMOD	_	_
13	%	_	NN	_	_	14	NMOD	_	_
14	rise	_	NN	_	_	10	OBJ	_	_
15	in	_	IN	_	_	14	LOC	_	_
16	earnings	_	NNS	_	_	15	PMOD	_	_
17	as	_	IN	_	_	10	ADV	_	_
18	American	_	NNP	_	_	20	NAME	_	_
19	Home	_	NNP	_	_	20	NAME	_	_
20	Products	_	NNPS	_	_	25	SBJ	_	_
21	Corp.	_	NNP	_	_	20	POSTHON	_	_
22	of	_	IN	_	_	20	NMOD	_	_
23	New	_	NNP	_	_	24	NAME	_	_
24	York	_	NNP	_	_	22	PMOD	_	_
25	posted	_	VBD	_	_	17	SUB	_	_
26	an	_	DT	_	_	29	NMOD	_	_
27	11	_	CD	_	_	28	AMOD	_	_
28	%	_	NN	_	_	29	NMOD	_	_
29	increase	_	NN	_	_	25	OBJ	_	_
30	in	_	IN	_	_	29	LOC	_	_
31	net	_	NN	_	_	30	PMOD	_	_
32	.	_	.	_	_	10	P	_	_

1	American	_	NNP	_	_	3	NAME	_	_
2	Home	_	NNP	_	_	3	NAME	_	_
3	Products	_	NNPS	_	_	0	ROOT	_	_

1	American	_	NNP	_	_	3	NAME	_	_
2	Home	_	NNP	_	_	3	NAME	_	_
3	Products	_	NNPS	_	_	4	SBJ	_	_
4	said	_	VBD	_	_	0	ROOT	_	_
5	sales	_	NNS	_	_	15	SBJ	_	_
6	and	_	CC	_	_	5	COORD	_	_
7	earnings	_	NNS	_	_	6	CONJ	_	_
8	for	_	IN	_	_	5	NMOD	_	_
9	the	_	DT	_	_	11	NMOD	_	_
10	third	_	JJ	_	_	11	NMOD	_	_
11	quarter	_	NN	_	_	8	PMOD	_	_
12	and	_	CC	_	_	11	COORD	_	_
13	nine	_	CD	_	_	14	NMOD	_	_
14	months	_	NNS	_	_	12	CONJ	_	_
15	were	_	VBD	_	_	4	OBJ	_	_
16	at	_	IN	_	_	15	LOC-PRD	_	_
17	record	_	NN	_	_	18	NMOD	_	_
18	levels	_	NNS	_	_	16	PMOD	_	_
19	.	_	.	_	_	4	P	_	_

1	Sales	_	NNS	_	_	6	SBJ	_	_
2	for	_	IN	_	_	1	NMOD	_	_
3	the	_	DT	_	_	5	NMOD	_	_
4	third	_	JJ	_	_	5	NMOD	_	_
5	quarter	_	NN	_	_	2	PMOD	_	_
6	increased	_	VBD	_	_	0	ROOT	_	_
7	6.5	_	CD	_	_	8	NMOD	_	_
8	%	_	NN	_	_	6	EXT	_	_
9	to	_	TO	_	_	6	DIR	_	_
10	$	_	$	_	_	9	PMOD	_	_
11	1.51	_	CD	_	_	10	DEP	_	_
12	billion	_	CD	_	_	10	DEP	_	_
13	from	_	IN	_	_	6	DIR	_	_
14	$	_	$	_	_	13	PMOD	_	_
15	1.42	_	CD	_	_	14	DEP	_	_
16	billion	_	CD	_	_	14	DEP	_	_
17	.	_	.	_	_	6	P	_	_

1	Sales	_	NNS	_	_	5	SBJ	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	health-care	_	JJ	_	_	4	NMOD	_	_
4	products	_	NNS	_	_	2	PMOD	_	_
5	increased	_	VBD	_	_	0	ROOT	_	_
6	6	_	CD	_	_	7	NMOD	_	_
7	%	_	NN	_	_	5	EXT	_	_
8	in	_	IN	_	_	5	TMP	_	_
9	the	_	DT	_	_	11	NMOD	_	_
10	third	_	JJ	_	_	11	NMOD	_	_
11	quarter	_	NN	_	_	8	PMOD	_	_
12	,	_	,	_	_	5	P	_	_
13	based	_	VBN	_	_	5	ADV	_	_
14	in	_	IN	_	_	13	PMOD	_	_
15	part	_	NN	_	_	14	PMOD	_	_
16	on	_	IN	_	_	13	PMOD	_	_
17	strong	_	JJ	_	_	18	NMOD	_	_
18	sales	_	NNS	_	_	16	PMOD	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	prescription	_	NN	_	_	21	NMOD	_	_
21	drugs	_	NNS	_	_	19	PMOD	_	_
22	such	_	JJ	_	_	23	DEP	_	_
23	as	_	IN	_	_	21	NMOD	_	_
24	Premarin	_	NNP	_	_	23	PMOD	_	_
25	,	_	,	_	_	24	P	_	_
26	an	_	DT	_	_	28	NMOD	_	_
27	estrogen-replacement	_	NN	_	_	28	NMOD	_	_
28	drug	_	NN	_	_	24	APPO	_	_
29	,	_	,	_	_	24	P	_	_
30	and	_	CC	_	_	18	COORD	_	_
31	sales	_	NNS	_	_	30	CONJ	_	_
32	of	_	IN	_	_	31	NMOD	_	_
33	the	_	DT	_	_	34	NMOD	_	_
34	company	_	NN	_	_	37	NMOD	_	_
35	's	_	POS	_	_	34	SUFFIX	_	_
36	infant	_	NN	_	_	37	NMOD	_	_
37	formula	_	NN	_	_	32	PMOD	_	_
38	.	_	.	_	_	5	P	_	_

1	American	_	NNP	_	_	3	NAME	_	_
2	Home	_	NNP	_	_	3	NAME	_	_
3	Products	_	NNPS	_	_	4	SBJ	_	_
4	said	_	VBD	_	_	0	ROOT	_	_
5	net	_	JJ	_	_	6	NMOD	_	_
6	income	_	NN	_	_	7	SBJ	_	_
7	benefited	_	VBD	_	_	4	OBJ	_	_
8	from	_	IN	_	_	7	ADV	_	_
9	a	_	DT	_	_	14	NMOD	_	_
10	``	_	``	_	_	14	P	_	_
11	lower	_	JJR	_	_	14	NMOD	_	_
12	effective	_	JJ	_	_	14	NMOD	_	_
13	tax	_	NN	_	_	14	NMOD	_	_
14	rate	_	NN	_	_	8	PMOD	_	_
15	,	_	,	_	_	14	P	_	_
16	''	_	''	_	_	14	P	_	_
17	reflecting	_	VBG	_	_	14	APPO	_	_
18	a	_	DT	_	_	19	NMOD	_	_
19	reduction	_	NN	_	_	17	OBJ	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	foreign	_	JJ	_	_	23	NMOD	_	_
22	tax	_	NN	_	_	23	NMOD	_	_
23	rates	_	NNS	_	_	20	PMOD	_	_
24	,	_	,	_	_	14	P	_	_
25	and	_	CC	_	_	14	COORD	_	_
26	additional	_	JJ	_	_	27	NMOD	_	_
27	operations	_	NNS	_	_	25	CONJ	_	_
28	in	_	IN	_	_	27	LOC	_	_
29	Puerto	_	NNP	_	_	30	NAME	_	_
30	Rico	_	NNP	_	_	28	PMOD	_	_
31	.	_	.	_	_	4	P	_	_

1	Net	_	NN	_	_	3	SBJ	_	_
2	also	_	RB	_	_	3	ADV	_	_
3	was	_	VBD	_	_	0	ROOT	_	_
4	aided	_	VBN	_	_	3	VC	_	_
5	by	_	IN	_	_	4	LGS	_	_
6	a	_	DT	_	_	7	NMOD	_	_
7	gain	_	NN	_	_	5	PMOD	_	_
8	on	_	IN	_	_	7	NMOD	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	sale	_	NN	_	_	8	PMOD	_	_
11	of	_	IN	_	_	10	NMOD	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	company	_	NN	_	_	16	NMOD	_	_
14	's	_	POS	_	_	13	SUFFIX	_	_
15	equity	_	NN	_	_	16	NMOD	_	_
16	interests	_	NNS	_	_	11	PMOD	_	_
17	in	_	IN	_	_	16	LOC	_	_
18	South	_	NNP	_	_	19	NAME	_	_
19	Africa	_	NNP	_	_	17	PMOD	_	_
20	effective	_	JJ	_	_	7	APPO	_	_
21	Sept.	_	NNP	_	_	20	TMP	_	_
22	1	_	CD	_	_	21	NMOD	_	_
23	.	_	.	_	_	3	P	_	_

1	In	_	IN	_	_	13	LOC	_	_
2	New	_	NNP	_	_	7	NMOD	_	_
3	York	_	NNP	_	_	7	NMOD	_	_
4	Stock	_	NNP	_	_	7	NMOD	_	_
5	Exchange	_	NNP	_	_	7	NMOD	_	_
6	composite	_	JJ	_	_	7	NMOD	_	_
7	trading	_	NN	_	_	1	PMOD	_	_
8	yesterday	_	NN	_	_	13	TMP	_	_
9	,	_	,	_	_	13	P	_	_
10	American	_	NNP	_	_	12	NAME	_	_
11	Home	_	NNP	_	_	12	NAME	_	_
12	Products	_	NNPS	_	_	13	SBJ	_	_
13	closed	_	VBD	_	_	0	ROOT	_	_
14	at	_	IN	_	_	13	ADV	_	_
15	$	_	$	_	_	14	PMOD	_	_
16	102.25	_	CD	_	_	15	NMOD	_	_
17	a	_	DT	_	_	18	NMOD	_	_
18	share	_	NN	_	_	15	ADV	_	_
19	,	_	,	_	_	13	P	_	_
20	down	_	IN	_	_	13	ADV	_	_
21	75	_	CD	_	_	22	NMOD	_	_
22	cents	_	NNS	_	_	20	AMOD	_	_
23	.	_	.	_	_	13	P	_	_

1	Pfizer	_	NNP	_	_	0	ROOT	_	_

1	Pfizer	_	NNP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	third-quarter	_	NN	_	_	4	NMOD	_	_
4	sales	_	NNS	_	_	5	SBJ	_	_
5	increased	_	VBD	_	_	2	OBJ	_	_
6	4	_	CD	_	_	7	NMOD	_	_
7	%	_	NN	_	_	5	EXT	_	_
8	to	_	TO	_	_	5	DIR	_	_
9	$	_	$	_	_	8	PMOD	_	_
10	1.44	_	CD	_	_	9	DEP	_	_
11	billion	_	CD	_	_	9	DEP	_	_
12	from	_	IN	_	_	5	DIR	_	_
13	$	_	$	_	_	12	PMOD	_	_
14	1.38	_	CD	_	_	13	DEP	_	_
15	billion	_	CD	_	_	13	DEP	_	_
16	.	_	.	_	_	2	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	company	_	NN	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	net	_	JJ	_	_	5	NMOD	_	_
5	income	_	NN	_	_	6	SBJ	_	_
6	was	_	VBD	_	_	3	OBJ	_	_
7	flat	_	JJ	_	_	6	PRD	_	_
8	because	_	IN	_	_	6	PRP	_	_
9	of	_	IN	_	_	8	DEP	_	_
10	investment	_	NN	_	_	8	PMOD	_	_
11	in	_	IN	_	_	10	NMOD	_	_
12	research	_	NN	_	_	11	PMOD	_	_
13	and	_	CC	_	_	12	COORD	_	_
14	development	_	NN	_	_	13	CONJ	_	_
15	and	_	CC	_	_	10	COORD	_	_
16	costs	_	NNS	_	_	15	CONJ	_	_
17	related	_	VBN	_	_	16	APPO	_	_
18	to	_	TO	_	_	17	AMOD	_	_
19	launches	_	NNS	_	_	18	PMOD	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	several	_	JJ	_	_	22	NMOD	_	_
22	products	_	NNS	_	_	20	PMOD	_	_
23	.	_	.	_	_	3	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	company	_	NN	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	dollar	_	NN	_	_	9	SBJ	_	_
6	's	_	POS	_	_	5	SUFFIX	_	_
7	continued	_	VBN	_	_	5	NMOD	_	_
8	strengthening	_	VBG	_	_	5	NMOD	_	_
9	reduced	_	VBD	_	_	3	OBJ	_	_
10	world-wide	_	JJ	_	_	12	NMOD	_	_
11	sales	_	NNS	_	_	12	NMOD	_	_
12	growth	_	NN	_	_	9	OBJ	_	_
13	by	_	IN	_	_	9	EXT	_	_
14	three	_	CD	_	_	16	NMOD	_	_
15	percentage	_	NN	_	_	16	NMOD	_	_
16	points	_	NNS	_	_	13	PMOD	_	_
17	.	_	.	_	_	3	P	_	_

1	Pfizer	_	NNP	_	_	2	SBJ	_	_
2	posted	_	VBD	_	_	0	ROOT	_	_
3	its	_	PRP$	_	_	5	NMOD	_	_
4	largest	_	JJS	_	_	5	NMOD	_	_
5	gains	_	NNS	_	_	2	OBJ	_	_
6	in	_	IN	_	_	5	LOC	_	_
7	healthcare	_	NN	_	_	8	NMOD	_	_
8	sales	_	NNS	_	_	6	PMOD	_	_
9	,	_	,	_	_	8	P	_	_
10	up	_	IN	_	_	8	NMOD	_	_
11	3	_	CD	_	_	12	NMOD	_	_
12	%	_	NN	_	_	10	AMOD	_	_
13	,	_	,	_	_	8	P	_	_
14	and	_	CC	_	_	8	COORD	_	_
15	consumer	_	NN	_	_	16	NMOD	_	_
16	products	_	NNS	_	_	14	CONJ	_	_
17	,	_	,	_	_	16	P	_	_
18	up	_	IN	_	_	16	NMOD	_	_
19	23	_	CD	_	_	20	NMOD	_	_
20	%	_	NN	_	_	18	AMOD	_	_
21	.	_	.	_	_	2	P	_	_

1	Sales	_	NNS	_	_	10	SBJ	_	_
2	by	_	IN	_	_	1	NMOD	_	_
3	the	_	DT	_	_	5	NMOD	_	_
4	specialty	_	NN	_	_	5	NMOD	_	_
5	chemicals	_	NNS	_	_	2	PMOD	_	_
6	and	_	CC	_	_	5	COORD	_	_
7	materials	_	NNS	_	_	9	NMOD	_	_
8	science	_	NN	_	_	9	NMOD	_	_
9	segments	_	NNS	_	_	6	CONJ	_	_
10	were	_	VBD	_	_	0	ROOT	_	_
11	flat	_	JJ	_	_	10	PRD	_	_
12	,	_	,	_	_	10	P	_	_
13	and	_	CC	_	_	10	COORD	_	_
14	sales	_	NNS	_	_	19	SBJ	_	_
15	by	_	IN	_	_	14	NMOD	_	_
16	the	_	DT	_	_	18	NMOD	_	_
17	agriculture	_	NN	_	_	18	NMOD	_	_
18	segment	_	NN	_	_	15	PMOD	_	_
19	declined	_	VBD	_	_	13	CONJ	_	_
20	5	_	CD	_	_	21	NMOD	_	_
21	%	_	NN	_	_	19	EXT	_	_
22	.	_	.	_	_	10	P	_	_

1	In	_	IN	_	_	8	LOC	_	_
2	the	_	DT	_	_	4	NMOD	_	_
3	health-care	_	JJ	_	_	4	NMOD	_	_
4	segment	_	NN	_	_	1	PMOD	_	_
5	,	_	,	_	_	8	P	_	_
6	pharmaceutical	_	JJ	_	_	7	NMOD	_	_
7	sales	_	NNS	_	_	8	SBJ	_	_
8	increased	_	VBD	_	_	0	ROOT	_	_
9	4	_	CD	_	_	10	NMOD	_	_
10	%	_	NN	_	_	8	EXT	_	_
11	and	_	CC	_	_	8	COORD	_	_
12	sales	_	NNS	_	_	16	SBJ	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	hospital	_	NN	_	_	15	NMOD	_	_
15	products	_	NNS	_	_	13	PMOD	_	_
16	increased	_	VBD	_	_	11	CONJ	_	_
17	1	_	CD	_	_	18	NMOD	_	_
18	%	_	NN	_	_	16	EXT	_	_
19	.	_	.	_	_	8	P	_	_

1	During	_	IN	_	_	6	TMP	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	quarter	_	NN	_	_	1	PMOD	_	_
4	,	_	,	_	_	6	P	_	_
5	Pfizer	_	NNP	_	_	6	SBJ	_	_
6	received	_	VBD	_	_	0	ROOT	_	_
7	federal	_	JJ	_	_	8	NMOD	_	_
8	approval	_	NN	_	_	6	OBJ	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	Procardia	_	NNP	_	_	11	NAME	_	_
11	XL	_	NNP	_	_	9	PMOD	_	_
12	,	_	,	_	_	11	P	_	_
13	a	_	DT	_	_	16	NMOD	_	_
14	calcium	_	NN	_	_	16	NMOD	_	_
15	channel	_	NN	_	_	16	NMOD	_	_
16	blocker	_	NN	_	_	11	APPO	_	_
17	approved	_	VBN	_	_	16	APPO	_	_
18	for	_	IN	_	_	17	ADV	_	_
19	both	_	DT	_	_	20	NMOD	_	_
20	angina	_	NN	_	_	18	PMOD	_	_
21	and	_	CC	_	_	20	COORD	_	_
22	hypertension	_	NN	_	_	21	CONJ	_	_
23	,	_	,	_	_	11	P	_	_
24	and	_	CC	_	_	11	COORD	_	_
25	Monorail	_	NNP	_	_	26	NAME	_	_
26	Piccolino	_	NNP	_	_	24	CONJ	_	_
27	,	_	,	_	_	26	P	_	_
28	used	_	VBN	_	_	26	APPO	_	_
29	to	_	TO	_	_	28	OPRD	_	_
30	open	_	VB	_	_	29	IM	_	_
31	obstructed	_	VBN	_	_	33	NMOD	_	_
32	coronary	_	JJ	_	_	33	NMOD	_	_
33	arteries	_	NNS	_	_	30	OBJ	_	_
34	.	_	.	_	_	6	P	_	_

1	In	_	IN	_	_	11	LOC	_	_
2	New	_	NNP	_	_	7	NMOD	_	_
3	York	_	NNP	_	_	7	NMOD	_	_
4	Stock	_	NNP	_	_	7	NMOD	_	_
5	Exchange	_	NNP	_	_	7	NMOD	_	_
6	composite	_	JJ	_	_	7	NMOD	_	_
7	trading	_	NN	_	_	1	PMOD	_	_
8	yesterday	_	NN	_	_	11	TMP	_	_
9	,	_	,	_	_	11	P	_	_
10	Pfizer	_	NNP	_	_	11	SBJ	_	_
11	closed	_	VBD	_	_	0	ROOT	_	_
12	at	_	IN	_	_	11	ADV	_	_
13	$	_	$	_	_	12	PMOD	_	_
14	67.75	_	CD	_	_	13	NMOD	_	_
15	a	_	DT	_	_	16	NMOD	_	_
16	share	_	NN	_	_	13	ADV	_	_
17	,	_	,	_	_	11	P	_	_
18	up	_	IN	_	_	11	ADV	_	_
19	75	_	CD	_	_	20	NMOD	_	_
20	cents	_	NNS	_	_	18	AMOD	_	_
21	.	_	.	_	_	11	P	_	_

1	Schering-Plough	_	NNP	_	_	0	ROOT	_	_

1	Schering-Plough	_	NNP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	sales	_	NNS	_	_	4	SBJ	_	_
4	gained	_	VBD	_	_	2	OBJ	_	_
5	2.7	_	CD	_	_	6	NMOD	_	_
6	%	_	NN	_	_	4	OBJ	_	_
7	to	_	TO	_	_	4	DIR	_	_
8	$	_	$	_	_	7	PMOD	_	_
9	743.7	_	CD	_	_	8	DEP	_	_
10	million	_	CD	_	_	8	DEP	_	_
11	from	_	IN	_	_	4	DIR	_	_
12	$	_	$	_	_	11	PMOD	_	_
13	724.4	_	CD	_	_	12	DEP	_	_
14	million	_	CD	_	_	12	DEP	_	_
15	.	_	.	_	_	2	P	_	_

1	In	_	IN	_	_	7	TMP	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	period	_	NN	_	_	1	PMOD	_	_
4	,	_	,	_	_	7	P	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	company	_	NN	_	_	7	SBJ	_	_
7	completed	_	VBD	_	_	0	ROOT	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	sale	_	NN	_	_	7	OBJ	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	its	_	PRP$	_	_	14	NMOD	_	_
12	European	_	JJ	_	_	14	NMOD	_	_
13	cosmetics	_	NNS	_	_	14	NMOD	_	_
14	businesses	_	NNS	_	_	10	PMOD	_	_
15	,	_	,	_	_	7	P	_	_
16	sold	_	VBD	_	_	7	COORD	_	_
17	a	_	DT	_	_	19	NMOD	_	_
18	majority	_	NN	_	_	19	NMOD	_	_
19	interest	_	NN	_	_	16	OBJ	_	_
20	in	_	IN	_	_	19	NMOD	_	_
21	its	_	PRP$	_	_	23	NMOD	_	_
22	Brazilian	_	JJ	_	_	23	NMOD	_	_
23	affiliate	_	NN	_	_	20	PMOD	_	_
24	,	_	,	_	_	16	P	_	_
25	and	_	CC	_	_	16	COORD	_	_
26	announced	_	VBD	_	_	25	CONJ	_	_
27	the	_	DT	_	_	28	NMOD	_	_
28	reorganization	_	NN	_	_	26	OBJ	_	_
29	of	_	IN	_	_	28	NMOD	_	_
30	its	_	PRP$	_	_	33	NMOD	_	_
31	over-the-counter	_	JJ	_	_	33	NMOD	_	_
32	drug	_	NN	_	_	33	NMOD	_	_
33	businesses	_	NNS	_	_	29	PMOD	_	_
34	into	_	IN	_	_	28	NMOD	_	_
35	a	_	DT	_	_	37	NMOD	_	_
36	new	_	JJ	_	_	37	NMOD	_	_
37	unit	_	NN	_	_	34	PMOD	_	_
38	,	_	,	_	_	37	P	_	_
39	Schering-Plough	_	NNP	_	_	42	NAME	_	_
40	Health	_	NNP	_	_	42	NAME	_	_
41	Care	_	NNP	_	_	42	NAME	_	_
42	Products	_	NNPS	_	_	37	APPO	_	_
43	.	_	.	_	_	7	P	_	_

1	These	_	DT	_	_	2	NMOD	_	_
2	actions	_	NNS	_	_	3	SBJ	_	_
3	did	_	VBD	_	_	0	ROOT	_	_
4	n't	_	RB	_	_	3	ADV	_	_
5	affect	_	VB	_	_	3	VC	_	_
6	results	_	NNS	_	_	5	OBJ	_	_
7	because	_	IN	_	_	5	PRP	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	gain	_	NN	_	_	18	SBJ	_	_
10	on	_	IN	_	_	9	NMOD	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	sale	_	NN	_	_	10	PMOD	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	the	_	DT	_	_	17	NMOD	_	_
15	European	_	JJ	_	_	17	NMOD	_	_
16	cosmetics	_	NNS	_	_	17	NMOD	_	_
17	businesses	_	NNS	_	_	13	PMOD	_	_
18	was	_	VBD	_	_	7	SUB	_	_
19	offset	_	VBN	_	_	18	VC	_	_
20	by	_	IN	_	_	19	LGS	_	_
21	provisions	_	NNS	_	_	20	PMOD	_	_
22	relating	_	VBG	_	_	21	APPO	_	_
23	to	_	TO	_	_	22	ADV	_	_
24	the	_	DT	_	_	26	NMOD	_	_
25	Brazil	_	NNP	_	_	26	NMOD	_	_
26	divestiture	_	NN	_	_	23	PMOD	_	_
27	and	_	CC	_	_	26	COORD	_	_
28	drug	_	NN	_	_	29	NMOD	_	_
29	restructuring	_	NN	_	_	27	CONJ	_	_
30	.	_	.	_	_	3	P	_	_

1	U.S.	_	NNP	_	_	3	NMOD	_	_
2	pharmaceutical	_	JJ	_	_	3	NMOD	_	_
3	sales	_	NNS	_	_	4	SBJ	_	_
4	rose	_	VBD	_	_	0	ROOT	_	_
5	15	_	CD	_	_	6	NMOD	_	_
6	%	_	NN	_	_	4	EXT	_	_
7	,	_	,	_	_	4	P	_	_
8	led	_	VBN	_	_	4	ADV	_	_
9	by	_	IN	_	_	8	LGS	_	_
10	allergy	_	NN	_	_	9	PMOD	_	_
11	,	_	,	_	_	10	P	_	_
12	asthma	_	NN	_	_	10	COORD	_	_
13	and	_	CC	_	_	12	COORD	_	_
14	cold	_	JJ	_	_	15	NMOD	_	_
15	products	_	NNS	_	_	13	CONJ	_	_
16	;	_	:	_	_	15	P	_	_
17	dermatological	_	JJ	_	_	18	NMOD	_	_
18	products	_	NNS	_	_	15	COORD	_	_
19	;	_	:	_	_	18	P	_	_
20	anti-infectives	_	NNS	_	_	18	COORD	_	_
21	and	_	CC	_	_	20	COORD	_	_
22	anti-cancer	_	JJ	_	_	23	NMOD	_	_
23	products	_	NNS	_	_	25	COORD	_	_
24	;	_	:	_	_	21	P	_	_
25	and	_	CC	_	_	21	CONJ	_	_
26	cardiovascular	_	JJ	_	_	27	NMOD	_	_
27	products	_	NNS	_	_	25	CONJ	_	_
28	.	_	.	_	_	4	P	_	_

1	World-wide	_	JJ	_	_	4	NMOD	_	_
2	consumer	_	NN	_	_	4	NMOD	_	_
3	product	_	NN	_	_	4	NMOD	_	_
4	sales	_	NNS	_	_	5	SBJ	_	_
5	declined	_	VBD	_	_	0	ROOT	_	_
6	12	_	CD	_	_	7	NMOD	_	_
7	%	_	NN	_	_	5	EXT	_	_
8	,	_	,	_	_	5	P	_	_
9	primarily	_	RB	_	_	10	PMOD	_	_
10	because	_	IN	_	_	5	PRP	_	_
11	of	_	IN	_	_	10	DEP	_	_
12	the	_	DT	_	_	15	NMOD	_	_
13	European	_	JJ	_	_	15	NMOD	_	_
14	cosmetics	_	NNS	_	_	15	NMOD	_	_
15	sale	_	NN	_	_	10	PMOD	_	_
16	.	_	.	_	_	5	P	_	_

1	Significantly	_	RB	_	_	2	AMOD	_	_
2	lower	_	JJR	_	_	3	NMOD	_	_
3	sales	_	NNS	_	_	12	SBJ	_	_
4	of	_	IN	_	_	3	NMOD	_	_
5	`	_	``	_	_	10	P	_	_
6	Stay	_	NNP	_	_	10	NMOD	_	_
7	Trim	_	NNP	_	_	10	NMOD	_	_
8	'	_	''	_	_	10	P	_	_
9	diet	_	NN	_	_	10	NMOD	_	_
10	aids	_	NNS	_	_	4	PMOD	_	_
11	also	_	RB	_	_	12	ADV	_	_
12	were	_	VBD	_	_	0	ROOT	_	_
13	a	_	DT	_	_	14	NMOD	_	_
14	factor	_	NN	_	_	12	PRD	_	_
15	in	_	IN	_	_	14	LOC	_	_
16	the	_	DT	_	_	17	NMOD	_	_
17	drop	_	NN	_	_	15	PMOD	_	_
18	.	_	.	_	_	12	P	_	_

1	The	_	DT	_	_	5	NMOD	_	_
2	Maybelline	_	NNP	_	_	5	NMOD	_	_
3	beauty	_	NN	_	_	5	NMOD	_	_
4	product	_	NN	_	_	5	NMOD	_	_
5	line	_	NN	_	_	6	SBJ	_	_
6	had	_	VBD	_	_	0	ROOT	_	_
7	higher	_	JJR	_	_	8	NMOD	_	_
8	sales	_	NNS	_	_	6	OBJ	_	_
9	following	_	VBG	_	_	6	TMP	_	_
10	a	_	DT	_	_	13	NMOD	_	_
11	sluggish	_	JJ	_	_	13	NMOD	_	_
12	first	_	JJ	_	_	13	NMOD	_	_
13	half	_	NN	_	_	9	PMOD	_	_
14	.	_	.	_	_	6	P	_	_

1	In	_	IN	_	_	9	LOC	_	_
2	Big	_	NNP	_	_	5	NMOD	_	_
3	Board	_	NNP	_	_	5	NMOD	_	_
4	composite	_	JJ	_	_	5	NMOD	_	_
5	trading	_	NN	_	_	1	PMOD	_	_
6	,	_	,	_	_	9	P	_	_
7	Schering-Plough	_	NNP	_	_	8	NMOD	_	_
8	shares	_	NNS	_	_	9	SBJ	_	_
9	fell	_	VBD	_	_	0	ROOT	_	_
10	75	_	CD	_	_	11	NMOD	_	_
11	cents	_	NNS	_	_	9	EXT	_	_
12	to	_	TO	_	_	9	OPRD	_	_
13	close	_	VB	_	_	12	IM	_	_
14	at	_	IN	_	_	13	ADV	_	_
15	$	_	$	_	_	14	PMOD	_	_
16	74.125	_	CD	_	_	15	NMOD	_	_
17	.	_	.	_	_	9	P	_	_

